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OBJECTIVES: The Chronic Care Model (CCM) is a framework for enhancing health
care delivery for chronic illnesses through six elements: self-management support,
delivery system design, community resources, organizational support, decision
support, and clinical information systems. The CCM was implemented at USAF
Wilford Hall Medical Center from 2006 through 2008, but little is known about its
long-term effectiveness. METHODS: We used the ARCHeS interface to the Archi-
medes model to forecast the effectiveness of the CCM compared to the current
levels of care in the US (CLC) over 20 years for patients with type 2 diabetes. We
modeled the CCM intervention effects on health outcomes and disease progression
of diabetes based on empirical biomarker change results from three-year military-
based clinical data. The primary analysis focused on the effectiveness in terms of
diabetes related health outcomes, while a secondary analysis considered cost-
effectiveness from a health care system perspective. RESULTS: Compared with
CLC, the relative reductions in 20-year Kaplan-Meier incidence due to the CCM
were 10.3%, 3.8%, 5.8%, 6.0%, 11.1% for myocardial infarction, proliferative diabetic
retinopathy, blindness, foot ulcer, and foot amputation, respectively. The CCM
resulted in a 6.7% relative reduction in coronary heart disease death, and a 0.6%
relative reduction in all-cause death. The CCM had no compelling benefits for
reducing the incidence of stroke or nephropathy. CONCLUSIONS: We found the
CCM lowers the risk of morbidity and mortality from diabetes in a military popu-
lation. Our results using ARCHeS simulations are broadly consistent with previous
Markov model studies but extend those results by providing a more detailed un-
derstanding of the specific health outcomes affected by the CCM, as well as the
impact on comorbidities associated with diabetes.
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DIET THERAPIES IN PATIENTS WITH TYPE-2 DIABETES: A MIXED-TREATMENT
COMPARISON OF RANDOMIZED CONTROL TRIALS
Harrington AR, Malone D
The University of Arizona, Tucson, AZ, USA
OBJECTIVES: Type 2 Diabetes Mellitus (TTDM) contributes to the body’s inability to
produce a sufficient amount of insulin in order to sustain glucose levels necessary
for energy production. The study aim is to determine the association between
multiple diet therapies and the clinical profile of adult patients with TTDM.
METHODS: We conducted a mixed-treatment comparison meta-analysis of ran-
domized diet therapies for TTDM patients. Therapies included high carbohydrate
and isocaloric (HCI); high carbohydrate and hypocaloric (HCH); low carbohydrate
and isocaloric (LCI); and low carbohydrate and hypocaloric (LCH). A systematic
literature search was conducted through December 2010. The primary outcomes
measured were hemoglobin A1c (HbA1c), high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, and triglycerides. These outcomes
were dichotomized based upon American Diabetes Association (ADA) standards. A
diet was considered successful if the patient’s HbA1c was 7%, HDL was 40
mg/dL, LDL was 100 mg/dL, or triglycerides were 150 mg/dL. Mixed-treatment
comparison meta-analysis was used to combine direct, within-trial, and between-
trial comparisons with indirect trial evidence from other trials while maintaining
randomization. Results are reported as odds ratios (OR) and 95% credible intervals
(CI). RESULTS: In total, 10 studies (21 treatment arms and 340 patients) were in-
cluded in the analysis. For bothHbA1c and triglycerides, theHCHdiet yielded lower
measurements compared to the HCI diet (OR: 0.89 CI: 0.04, 20.86; OR: 0.58 CI: 0.02,
15.55, respectively for HbA1c and triglycerides) and LCI diet (OR: 0.47 CI: 0.02, 7.45;
OR: 0.15 CI: 0.001, 6.28, respectively for HbA1c and triglycerides). LDL and HDL
cholesterol measurements were not found to be statistically significantly different
among the four diet types. CONCLUSIONS: This study illustrated no statistically
significant differences existed between the four types of diets with respect to four
clinical outcomes. Further research is necessary to identify an optimal diet combi-
nation for patients with TTDM.
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EFFECTIVENESS AND ADHERENCE WITH FIXED-DOSE COMBINATION (FDC)
VERSUS COADMINISTERED DUAL THERAPY (CDT) ANTIHYPERGLYCEMIC
REGIMENS: A META-ANALYSIS
Han S, Davies MJ, Lento K, Radican L, Zhang Q
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OBJECTIVES: To compare the effect of antihyperglycemic FDCs on A1C and adher-
ence relative to CDTs in clinical practice.METHODS: A 2-part systematic literature
review and meta-analysis were performed to compare the A1C response and ad-
herence between the 2 drug regimens. Inclusion criteria limited articles to studies
that compared equivalent drug components within FDC and CDT. Searches used
Medline, Embase, and Cochrane databases. Of the 1246 identified abstracts, 152
articles were reviewed, and 8met the inclusion criteria. Results were extracted and
pooled in a meta-analysis, using a random-effects model. Unreported standard
deviations were imputed according to the Cochrane Handbook. Cohort compari-
sons were described as mean differences (MD) with 95% confidence intervals (CIs).
RESULTS:A total of 37,173 patients comprised the 16 reported cohort comparisons.
Five comparisons described A1C reductions in FDC and CDT cohorts, and a meta-
analysis revealed a greater reduction in A1C with FDC (MD, 0.5% [95% CI: 0.8,
0.3%]). Eleven comparisons evaluated medication adherence (measured by med-
ication possession ratio [MPR]) between the FDC and CDT cohorts. These 11 cohort
comparisons were divided into 3 subgroups due to different study designs. Five
comparisons described MPR for FDC and CDT cohorts, with higher adherence with
FDC (MD, 12% [95% CI: 5, 19%]). Three comparisons examined patients who
switched from monotherapy to FDC or CDT, with higher adherence for patients
who switched to FDC (MD 8% [95%CI: 6, 10%]). Three comparisons described results
for patients who switched from CDT to FDC or stayed on CDT, with higher adher-
ence for patients who switched to FDC (MD 5% [95% CI, 3, 7%]). CONCLUSIONS:Use
of antihyperglycemic FDCs was associated with lower A1C levels and higher MPRs
compared to CDT in patients with T2DM in clinical practice.
PDB9
IMPACT OF EXENATIDE, PEN INSULIN AND VIAL/SYRINGE INSULIN ON
PATIENT OUTCOMES IN A DIABETES POPULATION IN THE UNITED STATES: A
RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE AND FIRST-YEAR
COSTS
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OBJECTIVES: The Objective of this research is to compare health care costs and
medication persistence for patients initiating treatment using exenatide, pen in-
sulin or vial insulin. METHODS: Commercial health plan data [2004 to 2008] were
used to identify episodes of anti-diabetic drug therapy which were then classified
according to treatment history: first observed treatment; restarting a previous ther-
apy [90-day gap in all treatment]; switching therapy; and augmentation therapy.
All exenatide and insulin episodes were selected for this analysis. Multivariate
statisticalmethods adjusted for demographics, drug use history, priormedical care
use, comorbidmedical conditions, and prescription drug profile. Several sensitivity
analyses were conducted. RESULTS: 213,701 episodes of anti-diabetic drug therapy
were identified of which 7,031 patients initiated using exenatide, 21,011 used vial
insulin [VI] and 422 used pen insulin [PI]. Time to all cause discontinuation [TTAD]
wasmeasured for the index drug and all diabetic-related drugs. Pen insulin [PI] was
discontinued 91 days earlier than exenatide [p0.0001], while vial insulin [VI] was
continued 18 days longer than exenatide [p0.01]. PI patients discontinued all
anti-diabetic drugs 34 days earlier than exenatide patients [p0.05] while ex-
enatide andVI patients exhibited similar TTAD for all drugs. Relative to vial insulin,
exenatide use was estimated to reduce first-year medical costs by $4,629
[p0.0001] which was sufficient to offset higher prescription drug costs for ex-
enatide [$519, p0.0001]. Similar cost results were found comparing exenatide to
pen insulin but were not statistically significant, likely due to the limited sample
size for pen insulin. These results were confirmed using propensity scorematching
estimation andwere robust across episode type.CONCLUSIONS: Patients initiating
drug therapy using exenatide incur lower post-treatment costs than similar pa-
tients who initiated treatment using insulin.
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PROXIES FOR TREATMENT RESPONSE
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OBJECTIVES: The Potential for Benefit conceptual model is a framework to identify
subgroups of patients with differential potential for response to treatment. Within
this context, we developed the ENSEMBLE Minimum Dataset (MDS), a collection of
patient reported measures, to assess patient heterogeneity. The objective of this
research is to provide evidence that ENSEMBLE MDSmeasures can be used to form
subgroups that are clinically and statisticallymeaningful in their ability to discrim-
inate proxies for treatment response. METHODS: A cross-sectional survey was
mailed to 3380 type 2 diabetes patients identified from a large administrative
claims database. ENSEMBLE MDS measures included: Total Illness Burden Index
(TIBI), EQ-5D, Psychological Health Questionnaire (PHQ-4), Perceived Stress Scale
(PSS-4), Perceived Social Support (MOS-SS), MacArthur Scale of Subjective Social
Status (M-SSS), MacArthur Income Question (MIQ), Barrett Simplified Measure of
Social Status (BSMSS), Self-reported Depression (DQ), and Self-Reported Health
(SRH). Proxies for treatment response were patient global impression of disease
severity (PGIS), patient global impression of improvement (PGII) and overall disease
burden. We assessed the ability of ENSEMBLE MDS measures to discriminate
among levels of PGIS, PGII, and burden via unadjusted, adjusted, and trend
analyses. RESULTS: A total of 724 patients responded with complete survey data
and were categorized into 3 levels on PGIS, PGII, and burden. TIBI, EQ-5D, PHQ-4,
PSS-4, MOS-SS, andM-SSS discriminated across the levels of PGIS, PGII, and burden
(p  0.05) for all analyses. DQ discriminated burden for all analyses (p  0.01) and
PGII and PGIS for unadjusted and trend analyses (p  0.05). BSMSS only showed
significant trend for burden (p 0.05).CONCLUSIONS: Results of this study provide
evidence that the componentmeasures of the ENSEMBLEMDSdiscriminate among
levels of disease severity, improvement, and burden. Future research includes test-
ing these measures in other disease areas, testing alternative patient reported
measures, and creating a composite scoring algorithm.
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COMPARISON OF MULTIVARIABLE-ADJUSTED LOGISTIC REGRESSION WITH
PROPENSITY SCORE-MATCHED, PROPENSITY SCORE-STRATIFIED, AND
PROPENSITY SCORE-ADJUSTED LOGISTIC REGRESSION MODELS
Khoza S, Barner JC, Richards K
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To compare the multivariable-adjusted logistic regression model
with the propensity score-matched, propensity score-stratified, and propensity
score-adjusted logistic regression models in estimating the effect of exposure to
antidepressant agents in increasing the risk of type 2 diabetesmellitus.METHODS:
A retrospective cohort study using the Texas Medicaid prescription claims data-
basewas conducted from January 1, 2002 to December 31, 2009. Patients aged 18-64
years with new prescriptions for antidepressants (exposed group) or benzodiaz-
epines (unexposed group) and without diabetes at cohort entry were included in
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the study. Propensity scores, which predicted exposure to antidepressant agents,
were used to create propensity score-matched, propensity score-stratified, and
propensity score-adjusted logistic regression models. RESULTS: A total of 44,715
patients formed the study sample. The risk estimates varied across different ana-
lyticmethods. The propensity score-matched logistic regressionmodel yielded the
highest risk estimate (Relative Risk [RR]  1.452; 95% Confidence Interval [CI]: 1.276 –
1.651), followed by themultivariable-adjusted logistic regressionmodel (RR1.319;
95% CI: 1.067 – 1.630) and the propensity score-stratified logistic regression model
(RR1.153; 95% CI: 1.033 – 1.287). The propensity score-adjusted regression model
yielded the smallest risk estimate (RR1.080; 95% CI: 0.968 – 1.205). CONCLUSIONS:
Propensity score techniques using pharmacy claims data with a limited number of
covariates yielded varying estimates of the treatment effect. The choice of the
propensity score technique may influence the magnitude of the treatment effect
estimate.
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USE OF ANTIDEPRESSANTS AND THE RISK OF DIABETES MELLITUS: A NESTED
CASE-CONTROL STUDY
Khoza S, Barner JC, Lawson K, Rascati KL, Wilson JP, Bohman TM
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To determine whether current use of antidepressants is associated
with increased risk of type 2 diabetesmellitus compared to former use.METHODS:
A nested case-control study was conducted within a cohort of 35,552 patients with
new antidepressant prescriptions from January 1, 2002 to December 31, 2009 using
Texas Medicaid. Patients aged 18-64 years and without diabetes at cohort entry
were included in the study. Antidepressant exposure was classified as current use
(within 6 month of diabetes diagnosis) and former use (6 months before diabetes
diagnosis). Conditional logistic regression was used to address the study objective.
RESULTS: A total 2,507 cases of incident diabetes and 10,028 matched control pa-
tients were identified. The average age was 44.9 (SD13.0) and themajority (75.6%)
were female. Compared to former use, current use of antidepressants was associ-
ated with a 2.1-fold increase in the risk of diabetes (Odds Ratio [OR]  2.108; 95%
Confidence Interval [CI]: 1.520 – 2.923). Compared to former use, current use of
tricyclic antidepressants (TCAs; OR2.279; 95% CI: 1.344 – 3.865), selective sero-
tonin reuptake inhibitors (SSRIs; OR2.241; 95% CI: 1.539 – 3.263), serotonin-nor-
epinephrine reuptake inhibitors (SNRIs; OR1.938; 95% CI: 1.135 – 3.310), and Other
(OR1.769; 95%CI: 1.090 – 2.872) were associatedwith an increased risk of diabetes.
Among current antidepressant users, there were no significant differences in the
risk of diabetes for SSRIs (OR0.833; 95% CI: 0.564 – 1.232), SNRIs (OR0.787; 95% CI:
0.480 – 1.280), and Other (OR0.673; 95% CI: 0.428 – 1.057), compared to TCAs.
CONCLUSIONS: Compared to former use, current use of antidepressants was as-
sociated with a two-fold increase in the risk of diabetes mellitus. This association
was also observedwhen current users of TCAs, SSRIs, SNRIs, andOther antidepres-
sants were compared with former users.
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USE OF ANTIDEPRESSANTS AND THE RISK OF DIABETES MELLITUS: A
RETROSPECTIVE COHORT STUDY
Khoza S, Barner JC, Lawson K, Rascati KL, Wilson JP, Bohman TM
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To determine whether: 1) use of antidepressants, compared to ben-
zodiazepines, increases the risk of type 2 diabetes mellitus; 2) individual antide-
pressant classes, compared to benzodiazepines, increases the risk of type 2 diabe-
tes; and 3) there are differences in the risk of type 2 diabetes among antidepressant
classes. METHODS: A retrospective cohort study using the Texas Medicaid pre-
scription claims database was conducted from January 1, 2002 to December 31,
2009. Patients aged 18-64 years with new prescriptions for antidepressant agents
(exposed) and benzodiazepines (unexposed) and without diabetes at cohort entry
constituted the base study population. Logistic regression analyses were used to
address the study objectives. RESULTS: A total of 44,715 patients formed the study
sample. Of these, 35,552 were exposed and 9,163 were unexposed. The average age
was 38.6 (SD14.2) and the majority (69.3%) were female. Use of antidepressants
was associated with an increased risk of diabetes (Relative Risk [RR]  1.396; 95%
Confidence Interval [CI]: 1.126 – 1.729) compared to benzodiazepine use, after con-
trolling for age, gender, medication adherence, persistence, number of diabeto-
genic medications, Chronic Disease Score, treatment duration, and year of cohort
entry. Compared to benzodiazepines, tricyclic antidepressants (TCAs; RR1.445;
95% CI: 1.057 – 1.977), serotonin-norepinephrine reuptake inhibitors (SNRIs;
RR1.593; 95% CI: 1.160 – 2.186), and selective serotonin reuptake inhibitors (SSRIs;
RR1.317; 95% CI: 1.037 – 1.673), were associated with an increased risk for diabe-
tes. Compared to TCAs, there were no significant differences in the risk of diabetes
for SSRIs (RR0.876; 95% CI: 0.678 – 1.132), SNRIs (RR1.003; 95% CI: 0.734 – 1.371)
and Other antidepressants (RR0.785; 95% CI: 0.582 – 1.058). CONCLUSIONS: Over-
all, use of antidepressants was associated with an increased risk of diabetes mel-
litus compared to benzodiazepine use. This association was also observed when
tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin-
norepinephrine reuptake inhibitors were compared to benzodiazepines.
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USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE
OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS
WITH TYPE-2 DIABETES
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OBJECTIVES: Understanding the benefit-risk profiles of medications for type 2 di-
abetes (T2D) is of high public health interest. We assessed the potential compara-
tive health benefits and risks of exenatide onceweekly (ExQW) compared to insulin
glargine (IG) under various assumptions about hypothetical risks from pancreatic
and thyroid cancer associated with either treatment. METHODS: Safety and effi-
cacy data from the randomized controlled DURATION-3 trial were incorporated
into the CORE Diabetes Model to predict long-term health outcomes; pancreatic
and thyroid cancer risks from SEER (general population); i3/MarketScan claims
databases (T2D and/or therapy) were incorporated into derived Markov model.
Incremental net health benefit (INHB) was estimated in life years (LYs) and quality-
adjusted life years (QALYs) (both discounted at 3%) for different timehorizons (base
case30 years) and different assumptions about cancer risks. The incidence rate of
pancreatic cancer was 1.17/10,000 population/year. In the base-case scenario no
increased pancreatic cancer risk from ExQWand relative risk (RR) of 1.25 for IGwas
assumed. The risk for thyroid cancer was assumed same as in general population
and equal for ExQW and IG. In two alternative scenarios for pancreatic cancer risk:
a) assuming IG RR1.33 and ExQW having no increased risk, and b) assuming
ExQW RR1.07 and IG RR1.25. RESULTS: The INHB for ExQW versus IG was 0.118
Lys and 0.239 QALYs in basecase; 0.119 LYs and 0.239 QALYs in scenario a); and
0.118 LYs and 0.238 QALYs in scenario b). Neither scenario a) or b) changed INHB by
more than1%. The INHB for ExQW remained positive under different assumptions
about time horizon and risk levels. CONCLUSIONS: In all scenarios modeled, the
INHB for ExQWwas positive compared to IG. This study suggests that the potential
benefits from ExQW in reducing established T2D complications are expected to
outweigh hypothetical risks from pancreatic and thyroid cancer.
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SHORT-TERM ASSOCIATION OF ANTIDEPRESSANT DRUG USE, LIFE-STYLE RISK
FACTORS AND NEW-ONSET DIABETES
Wilkins TL, Sambamoorthi U
West Virginia University, Morgantown, WV, USA
OBJECTIVES: The objective of the current study is to assess the short-term associ-
ation between antidepressant drug use and the risk of new-onset diabetes using
two years of observation. METHODS: This study used the longitudinal data on
26,990 adults over age 21 from the Medical Expenditure Panel Survey (MEPS), a
large-survey of families and individuals to produce national estimates of health-
care use and expenditures. We pooled longitudinal data for years 2004-2007. De-
pression and diabetes status were identified from the MEPS household files and
medical condition files. Antidepressant use was derived from prescription drug
reports. Chi-square tests and logistic regressions were used to examine the link
between antidepressant use interacted with depression, and new-onset diabetes,
after controlling for demographic, socio-economic, healthcare access, health sta-
tus, and life-style risk factors (obesity, smoking, and physical activity). The inde-
pendent variables were entered in blocks. RESULTS: Antidepressants use was re-
ported in 11% of individuals. In unadjusted models, the risk of new-onset diabetes
was significantly increased for persons using antidepressants with depression
((AOR2.12) compared with those who did not have either. When lifestyle risk
factors were entered in the model, statistical significance disappeared. Indepen-
dently, lifestyle risk factors significantly increased the risk of new-onset diabetes:
hypertension, lipid disorders, obesity, and no physical exercise. CONCLUSIONS:
We found no association between new onset diabetes and antidepressant use and
confirmed the association between life-style risk factors and new-onset diabetes.
Future studies on the risk of new-onset diabetes by duration and intensity of anti-
depressant use and depressive symptoms are needed.
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DIABETES MELLITUS TYPE 2 AND T2DM PLUS HYPERTENSION IN BRAZIL: THE
EPIDEMIOLOGIC PROFILE OF THE POPULATION REGISTERED IN THE
GOVERNMENT PROGRAM HIPERDIA
Nasciben V, Melo TG
Boehringer Ingelheim Brazil, Sao Paulo, Brazil
OBJECTIVES: Diabetes represents a burden to the health care system due to its
increasing rates of incidence, morbidity andmortality. Epidemiological data is cru-
cial for policy and decision making to clarify gaps in the current health program
and to develop new ones. We decided to review the status of the population regis-
tered at Hiperdia program in order to better understand the real situation of these
diseases.METHODS: HIPERDIA is a program for monitoring hypertensive/ diabetic
outpatients under the public healthcare system care. Based on that database, we
searched the general profile of this population from 2002 until 2010 focusing on
type 2 diabetes (T2DM) and T2DM plus hypertension, and also geographical distri-
bution, gender, age and overweight/ obesity prevalence were raised. RESULTS:
From 2002 to 2010, a total of 2,199,972 people with T2DM and T2DM plus Hyperten-
sion were registered in the database, with 12.5 % presenting T2DM only and 87.5 %
with both conditions, which represents about 1.5% of the total population under
the public healthcare system. For patients with T2DM only we found 114,836 men
and 159,581 women (41.8% and 58.2%) and for patients with both conditions we
found 619,005 men and 1,306,550 women (32.1% and 67.9%). Regarding age, the
majority of the patients are in between 50 - 70 years-old. Almost 50% of the patients
are distributed within 5 states SP, MG, BA, PR and RJ. Overweight or obesity was
present in 48% of this population. CONCLUSIONS: In accordance with epidemio-
logical data, most of the diabetic patients in this database are middle-age, women
and almost half of them are obese or overweight. Added to that, our estimates
about diabetes prevalence were different from the number reported by the Brazil-
ian MoH at 2008 (9.7%).
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